Publication | Open Access

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Translational MedicineMedicineMelanomaIpilimumab TreatmentClinical TrialsImmune Checkpoint InhibitorDermatologyCheckmate 172Cancer TreatmentOncologyRare Melanoma SubtypesMolecular Oncology